標(biāo)題: Titlebook: Sickle Cell Disease and Hematopoietic Stem Cell Transplantation; Emily Riehm Meier,Allistair Abraham,Ross M. Fasano Book 2018 Springer Int [打印本頁(yè)] 作者: 是英寸 時(shí)間: 2025-3-21 19:22
書(shū)目名稱(chēng)Sickle Cell Disease and Hematopoietic Stem Cell Transplantation影響因子(影響力)
書(shū)目名稱(chēng)Sickle Cell Disease and Hematopoietic Stem Cell Transplantation影響因子(影響力)學(xué)科排名
書(shū)目名稱(chēng)Sickle Cell Disease and Hematopoietic Stem Cell Transplantation網(wǎng)絡(luò)公開(kāi)度
書(shū)目名稱(chēng)Sickle Cell Disease and Hematopoietic Stem Cell Transplantation網(wǎng)絡(luò)公開(kāi)度學(xué)科排名
書(shū)目名稱(chēng)Sickle Cell Disease and Hematopoietic Stem Cell Transplantation被引頻次
書(shū)目名稱(chēng)Sickle Cell Disease and Hematopoietic Stem Cell Transplantation被引頻次學(xué)科排名
書(shū)目名稱(chēng)Sickle Cell Disease and Hematopoietic Stem Cell Transplantation年度引用
書(shū)目名稱(chēng)Sickle Cell Disease and Hematopoietic Stem Cell Transplantation年度引用學(xué)科排名
書(shū)目名稱(chēng)Sickle Cell Disease and Hematopoietic Stem Cell Transplantation讀者反饋
書(shū)目名稱(chēng)Sickle Cell Disease and Hematopoietic Stem Cell Transplantation讀者反饋學(xué)科排名
作者: 旁觀者 時(shí)間: 2025-3-21 23:05 作者: ELATE 時(shí)間: 2025-3-22 01:15 作者: 打擊 時(shí)間: 2025-3-22 05:35
Steven J. Hardy,Jasmine R. Holt,Amanda L. Thompsonr pluripotenten Stammzelle des Ektoderms ausgehen k?nnen, unterscheidet man verschiedene Typen. Zu nennen sind hier die keratinozyt?ren N?vi (verruk?se, epidermale N?vi mit und ohne Akantholyse, line?re Porokeratose, inflammatorische epidermale N?vi), die Follikeln?vi (z.B. Haarfollikeln?vus, N?vus 作者: 性滿足 時(shí)間: 2025-3-22 10:38 作者: CAJ 時(shí)間: 2025-3-22 15:06 作者: 揉雜 時(shí)間: 2025-3-22 18:04
ffen sie zu einem Auskunftsmittel, dessen sich diese hohen Kreise in vergangenen Zeiten bei ?hnlichen Anl?ssen nicht selten bedient hatten. Sofern zwei Angeh?rige beider Linien sich heirateten und in Gütergemeinschaft traten, war über den Ertrag und die Vers waltung der Herrschaften Trachenberg und 作者: 錯(cuò)誤 時(shí)間: 2025-3-22 23:29 作者: 漂泊 時(shí)間: 2025-3-23 01:24 作者: Visual-Field 時(shí)間: 2025-3-23 07:41 作者: 發(fā)電機(jī) 時(shí)間: 2025-3-23 13:35
http://image.papertrans.cn/s/image/866972.jpg作者: Locale 時(shí)間: 2025-3-23 14:34 作者: OGLE 時(shí)間: 2025-3-23 22:02 作者: 沖突 時(shí)間: 2025-3-23 23:28 作者: cliche 時(shí)間: 2025-3-24 05:20
Sickle Cell Disease and Hematopoietic Stem Cell Transplantation978-3-319-62328-3作者: Graduated 時(shí)間: 2025-3-24 10:13
tem Cell Transplantation. is a valuable resource for physicians and researchers dealing with and interested in this challenging, yet exciting, curative therapy for sickle cell disease, that will help guide patient management and stimulate investigative efforts..978-3-319-87292-6978-3-319-62328-3作者: 有效 時(shí)間: 2025-3-24 11:29 作者: 現(xiàn)任者 時(shí)間: 2025-3-24 15:11 作者: endoscopy 時(shí)間: 2025-3-24 21:44 作者: 窒息 時(shí)間: 2025-3-25 02:36 作者: 是限制 時(shí)間: 2025-3-25 06:11
Alexander Ngwube,Shalini Shenoyents of the Lassa virus genome. We then review the tools used to obtain viral genomic sequences used for phylogeny and molecular diagnostics, before shifting to a population perspective to assess the contributions of phylogenetic analysis in understanding the evolution and ecology of Lassa virus in 作者: gain631 時(shí)間: 2025-3-25 08:41
Alexis Leonard,Allistair Abrahamhres siebzehnten Geburtstages, als sie am 9. August 1822 unter den Traualtar trat. Sie ahnte schwerlich, da? sie mit diesem Schritt ihr Lebensglück jener gesch?ftlichen Transaktion zum Opfer brachte. Von der ersten Stunde an gestaltete sich das Schicksal der Neuverm?hlten trostlos: Entt?uschung folg作者: 神化怪物 時(shí)間: 2025-3-25 11:50 作者: 敲詐 時(shí)間: 2025-3-25 19:21
Clinical Manifestations of Sickle Cell Disease Across the Lifespan aging SCD population is facing multifaceted effects from acute-on-chronic vascular, inflammatory, and thrombotic injury, and life expectancy for adults with sickle cell anemia remains stubbornly stagnant in the fifth decade of life. Here, we review what is known about the clinical manifestations of作者: NEX 時(shí)間: 2025-3-25 22:07 作者: Tempor 時(shí)間: 2025-3-26 01:37 作者: 痛苦一下 時(shí)間: 2025-3-26 08:09 作者: 混合,攙雜 時(shí)間: 2025-3-26 08:51 作者: LUT 時(shí)間: 2025-3-26 16:32 作者: Harness 時(shí)間: 2025-3-26 17:49 作者: prosthesis 時(shí)間: 2025-3-27 00:52 作者: 預(yù)測(cè) 時(shí)間: 2025-3-27 04:26
Neurological Manifestations of Sickle Cell Disease and Their Impact on Allogeneic Hematopoietic Stemith SCA and the impact of pre-existing neurological conditions on HSCT complications and outcomes. We identify knowledge gaps and highlight recent developments. We also suggest a standardized clinical approach for assessing neurological complications of SCA before, during, and after HSCT.作者: 自負(fù)的人 時(shí)間: 2025-3-27 08:29
Overview of Hematopoietic Stem Cell Transplantation for Nonmalignant Diseaseslism, and aplastic anemia and bone marrow failure syndromes. Furthermore, it touches on recent developments in reduced intensity conditioning regimens, GVHD prophylaxis, and the management of post-transplant infection risks.作者: 財(cái)產(chǎn) 時(shí)間: 2025-3-27 12:19 作者: 過(guò)去分詞 時(shí)間: 2025-3-27 15:47 作者: degradation 時(shí)間: 2025-3-27 19:08
Haploidentical Hematopoietic Cell Transplantation for Sickle Cell Diseaseransplant conditioning regimen have led to promising results from ongoing clinical trials. Ultimately, innovative approaches such as cell therapies may be needed to make haploidentical transplantation a safe and effective curative option for sickle cell disease.作者: 空中 時(shí)間: 2025-3-27 23:00 作者: CANE 時(shí)間: 2025-3-28 05:09 作者: 槍支 時(shí)間: 2025-3-28 07:06 作者: Myelin 時(shí)間: 2025-3-28 10:57
Current Non-HSCT Treatments for SCDth care and public policies have successfully reduced the mortality in children with SCD and has led to its evolution into a chronic disease in adults living with SCD. While management of SCD remains largely symptomatic with only one FDA-approved pharmacologic disease-modifying agent hydroxyurea, im作者: Keratin 時(shí)間: 2025-3-28 15:29
Risk-Based Therapies for Sickle Cell Diseasempared to patients with HbSC or HbSβ.thalassemia. However, clinical complications vary dramatically, even among patients with the same genotype. One of the most fascinating and frustrating aspects of sickle cell care is how people with the same single amino acid substitution can have different clini作者: cavity 時(shí)間: 2025-3-28 19:35
Transfusion Support of the Patient with Sickle Cell Disease Undergoing Transplantation is the only curative therapy to date. Complications of transfusion therapy, including alloimmunization and iron overload, may potentially impact curative future HSCT. These sequelae may influence decisions relating to hematopoietic stem cell (HSC) donor selection, the level of conditioning regimen 作者: 土坯 時(shí)間: 2025-3-28 23:28
Neurological Manifestations of Sickle Cell Disease and Their Impact on Allogeneic Hematopoietic Stemren with sickle cell anemia (SCA) historically have had higher stroke risk than any other group of children outside of the perinatal period. Overt strokes are widely accepted as an indication for curative allogeneic hematopoietic stem cell transplantation (HSCT). As we learn more about the broad spe作者: Fibroid 時(shí)間: 2025-3-29 03:49 作者: Blatant 時(shí)間: 2025-3-29 09:47
Unique Challenges of Hematopoietic Stem Cell Transplant for Sickle Cell Diseasestem cell transplant. These include a relative paucity of fully matched unrelated donors compared to other underlying indications for transplant, an increased risk for neurovascular complications and sequelae related to existing endothelial dysfunction. As transplant conditioning regimens are being 作者: Figate 時(shí)間: 2025-3-29 13:15
The Ethics of Hematopoietic Stem Cell Transplantation for Sickle Cell Diseaseanswers. Five such important questions include: (1) Should HSCT be offered to children with less severe SCD? (2) Should assisted reproductive technology be used to conceive sibling donors? (3) Should HSCT be offered to children with significant social concerns? (4) Should children from low-income co作者: 傳授知識(shí) 時(shí)間: 2025-3-29 17:53 作者: Type-1-Diabetes 時(shí)間: 2025-3-29 22:38 作者: 無(wú)關(guān)緊要 時(shí)間: 2025-3-30 01:39
Matched Sibling Donor Hematopoietic Stem Cell Transplantation for Sickle Cell DiseaseThe worldwide experience with HSCT for sickle cell disease is predominantly with matched-related donors (MRDs). Conditioning regimens have historically been myeloablative, still considered by many to be standard of care when HSCT is performed for this disease. Efforts are underway to reduce the acut作者: 勾引 時(shí)間: 2025-3-30 05:53 作者: 急急忙忙 時(shí)間: 2025-3-30 11:26
Haploidentical Hematopoietic Cell Transplantation for Sickle Cell Disease of patients have such a donor. Haploidentical (i.e., half human leukocyte antigen (HLA)-matched relatives) could potentially solve this donor issue and thus provide a treatment option for essentially every patient. Ongoing investigation using either in vivo or ex vivo T-cell depletion strategies ha作者: 橫截,橫斷 時(shí)間: 2025-3-30 16:26
Gene Therapy: The Path Toward Becoming a Realistic Cure for Sickle Cell Disease the only currently available curative option for patients with SCD. Data suggests an overall survival of >95% with a myeloablative regimen using HLA-matched sibling donors and >90% disease-free survival using a non-myeloablative regimen, yet less than 15% of patients with SCD have an appropriately 作者: 投射 時(shí)間: 2025-3-30 20:13
Book 2018 reviews new data about risk prediction for severe SCD, outlines the unique challenges of ?HSCT for patients with SCD, profiles the supportive care guidelines for patients who are undergoing HSCT, highlights our current understanding of the best transfusion support for SCD patients prior to, during
